


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31200373</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1933-0693</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of neurosurgery</Title>
                <ISOAbbreviation>J. Neurosurg.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long-term outcome in orbital meningiomas: progression-free survival after targeted resection combined with early or postponed postoperative radiotherapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-11</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3171/2019.3.JNS181760</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">2019.3.JNS181760</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In meningiomas involving the orbit and optic canal, surgery is the mainstay of therapy. However, radical resection is often limited to avoid functional damage, so multidisciplinary treatment concepts are implemented. Data on the timing and value of early postoperative radiotherapy (PORT) are scarce. This retrospective study analyzes outcomes in patients who underwent targeted resection alone or in combination with early PORT.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients undergoing resection of orbit-associated WHO grade I meningiomas from January 1999 to December 2013 who presented to the authors' department at least twice for follow-up were included. Clinical and radiological findings were analyzed retrospectively. Patients were stratified into two cohorts: follow-up with MRI scans at regular intervals, i.e., the watch and wait (W&amp;W) group, and a PORT group receiving PORT within 6 months after surgery in addition to MRI follow-up. Patients in the W&amp;W group were scheduled for treatment when tumor progression was detected by imaging.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred twenty-two patients were included. The mean follow-up was 70 months. The most common symptoms at presentation were visual disturbances; 87.7% of patients received Simpson grade II-III targeted partial resection. Twenty-three patients received PORT, and 99 patients were regularly observed with MRI scans (W&amp;W group). Tumor recurrence/progression occurred significantly later (76.3 vs 40.7 months) and less frequently in the PORT group (13%) than in the W&amp;W group (46.5%). Cases of recurrence were diagnosed an average of 39 months after initial surgery in both groups. PORT patients demonstrated significantly less visual impairment at last follow-up.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results indicate that receiving PORT early after targeted partial resection might help to postpone tumor recurrence and the need for additional treatment, while preserving or even improving visual outcome.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Terpolilli</LastName>
                    <ForeName>Nicole Angela</ForeName>
                    <Initials>NA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of1Neurosurgery.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>6German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ueberschaer</LastName>
                    <ForeName>Moritz</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of1Neurosurgery.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>6German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Niyazi</LastName>
                    <ForeName>Maximilian</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>2Radiation Oncology.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>6German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hintschich</LastName>
                    <ForeName>Christoph</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>3Ophthalmology, and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>6German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Egensperger</LastName>
                    <ForeName>Rupert</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>4Neuropathology, University Hospital, LMU Munich.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>6German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muacevic</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>5European Cyberknife Center, Munich; and.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thon</LastName>
                    <ForeName>Niklas</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of1Neurosurgery.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>6German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tonn</LastName>
                    <ForeName>JÃ¶rg-Christian</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of1Neurosurgery.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>6German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schichor</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of1Neurosurgery.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>6German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosurg</MedlineTA>
            <NlmUniqueID>0253357</NlmUniqueID>
            <ISSNLinking>0022-3085</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CN = cranial nerve</Keyword>
            <Keyword MajorTopicYN="N">EBRT = external beam radiation therapy</Keyword>
            <Keyword MajorTopicYN="N">PFS = progression-free survival</Keyword>
            <Keyword MajorTopicYN="N">PORT = postoperative radiotherapy</Keyword>
            <Keyword MajorTopicYN="N">W&amp;W = watch and wait</Keyword>
            <Keyword MajorTopicYN="N">meningioma</Keyword>
            <Keyword MajorTopicYN="N">oncology</Keyword>
            <Keyword MajorTopicYN="N">orbital tumor</Keyword>
            <Keyword MajorTopicYN="N">outcome</Keyword>
            <Keyword MajorTopicYN="N">radiotherapy</Keyword>
            <Keyword MajorTopicYN="N">skull base</Keyword>
            <Keyword MajorTopicYN="N">sphenoorbital tumor</Keyword>
            <Keyword MajorTopicYN="N">targeted resection</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31200373</ArticleId>
            <ArticleId IdType="doi">10.3171/2019.3.JNS181760</ArticleId>
            <ArticleId IdType="pii">2019.3.JNS181760</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

